Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device
August 14, 2024 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
July 31, 2024 08:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us
July 18, 2024 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference
June 20, 2024 08:30 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
May 24, 2024 17:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
April 22, 2024 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union
March 28, 2024 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision...
Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US
December 18, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical...
Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis
October 18, 2023 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical...
Apple Approves Use of Avalon GloboCare’s KetoAir Mobile Application
October 04, 2023 09:00 ET
|
Avalon GloboCare Corp.
KetoAir™ Mobile Application Launches in Apple App Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon...